| Heading: |
Pancreatic Enzyme Replacement Therapy |
| Question ID: |
1760538 |
| UIN: |
27814 |
| House: |
Commons |
| Date tabled: |
2025-01-30 |
| Asking Member ID: |
5357 |
| Asking Member display name: |
Ayoub Khan
|
| Asking Member handle: |
AyoubKhanMP
|
| Asking Member Twitter reference: |
@AyoubKhanMP
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 6 January 2025 to Question 20760 on Pancreatic Enzyme Replacement Therapy, whether he has had recent discussions with Cabinet colleagues on increasing the UK's manufacturi |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-02-05 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
There have been no recent discussions with Cabinet Office colleagues on increasing the United Kingdom’s manufacturing capacity of pancreatic enzyme replacement therapy (PERT) or increasing access to the raw ingredients required for the production of PERT.... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |